regorafenib - For the treatment of metastatic and/or unresectable gastrointestinal stromal tumors (GIST) in patients who have had disease progression on, or intolerance to,
imatinib and sunitinib, according to specific criteria
ruxolitinib - For patients with intermediate to high risk symptomatic myelofibrosis, or patients with symptomatic splenomegaly, according to specific criteria
Exceptional Access Program
ruxolitinib - For the treatment of patients with polycythemia vera according to criteria.